Immunoprecise Stock Price, News & Analysis

ImmunoPrecise Antibodies (NASDAQ: IPA) announced its rebranding to MindWalk and a ticker symbol change to HYFT, marking its transformation into a Bio-Native AI platform company. The rebranding unifies ImmunoPrecise Antibodies, BioStrand, and Talem subsidiaries under a single corporate identity.

The company is evolving from a specialized wet-lab services provider to an integrated platform business powered by its LensAI™ platform with HYFT® technology. This transformation enables MindWalk to offer Data-as-a-Service (DaaS) and Software-as-a-Service (SaaS) solutions while expanding into asset generation and large-scale partnerships across the pharmaceutical industry.

ImmunoPrecise Antibodies (NASDAQ: IPA) announced its participation in the upcoming 27th Annual H.C. Wainwright Global Investment Conference, scheduled for September 8-10th, 2025, in New York. Dr. Jennifer Bath, the company's President and CEO, will deliver a corporate presentation and be available for one-on-one meetings with investors throughout the event.

Interested investors can schedule meetings with IPA's management team through their H.C. Wainwright representative or by emailing meetings@hcwco.com.

ImmunoPrecise Antibodies (NASDAQ: IPA) has reached a significant milestone in its universal dengue vaccine development program. Following the June discovery of a unique conserved dengue epitope using their LENSai™ platform with HYFT® technology, the company is advancing to preclinical manufacturing for in vivo testing.

The company will conduct immunization studies in rabbit models at their Canadian facility to evaluate the vaccine candidate's ability to generate monoclonal antibody responses. This progression demonstrates IPA's end-to-end capabilities, combining AI-driven discovery with wet-lab validation. The platform's approach aligns with FDA's encouragement of predictive, human-relevant methods that reduce animal testing reliance.

ImmunoPrecise Antibodies (NASDAQ: IPA) has announced the sale of its Netherlands subsidiary, IPA Europe, to AVS Bio for $12 million USD, generating net proceeds of $11.7 million USD on a cash-free, debt-free basis.

The strategic divestment allows IPA to streamline operations and focus resources on its AI-based Software as a Service (SaaS) platform, LENSai™, powered by HYFT® multi-omics technology. The transaction includes a 12-month Transition Services Agreement to ensure operational continuity.

The proceeds will be used to invest in scientific platforms, data-driven discovery technologies, and expansion of key strategic programs, reinforcing IPA's commitment to accelerating biologics discovery through AI innovation.

AVS Bio, a portfolio company of Arlington Capital Partners, has acquired ImmunoPrecise Antibodies Europe (IPA Europe) from ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA). The acquisition strengthens AVS Bio's European presence and expands its capabilities in antibody discovery, protein expression, and organoid growth factor development.

IPA Europe, with facilities in Utrecht and Oss, Netherlands, provides comprehensive antibody discovery and characterization services, featuring advanced hybridoma and B-cell screening platforms. The company will maintain its existing management structure while operating as a strategic European hub within AVS Bio's network, serving pharmaceutical customers in both human and animal health markets.

ImmunoPrecise Antibodies (NASDAQ: IPA), a bio-native AI company, reported its fiscal year 2025 results with notable achievements. The company delivered record Q4 revenue of $7.0M and its best-ever quarterly Adjusted EBITDA of ($0.3M). Full-year revenue reached $24.5M, with gross margin expanding to 55% from 49% year-over-year.

The company's BioStrand segment grew over 180% in FY2025, now representing over 5% of total revenue with margins approaching 90%. IPA secured a strategic USD $8-10M partnership for antibody-drug conjugates development and demonstrated successful results with its LENSai platform, including breakthrough findings in dengue virus research and GLP-1 peptides development.

The company is strategically realigning to focus on AI-based product development and plans to complete the divestiture of its Dutch subsidiary to streamline operations.

ImmunoPrecise Antibodies (NASDAQ: IPA) has announced expanded study results for its LENSai™ Immunogenicity Screening technology, demonstrating its ability to predict Anti-Drug-Antibody (ADA) risk in therapeutic proteins before clinical trials. The study analyzed 217 marketed and clinical-stage antibodies, achieving a powerful discriminative capability with AUC=0.92.

The technology addresses a critical industry challenge, as up to 40% of biologics fail in late development due to ADA-related issues, resulting in potential losses of $1-2 billion per biologic. LENSai's HYFT-powered screening can evaluate nearly 900 HLA variants in one overnight run, offering significant time and cost advantages over traditional methods.

ImmunoPrecise Antibodies (NASDAQ: IPA), a bio-native AI company, has appointed Jeff Fried to its Advisory Board. Fried, currently Director of Platform Strategy and Innovations at InterSystems, brings over 25 years of experience in healthcare data infrastructure and AI innovation.

Fried has been a strong advocate for IPA's LENSai™ platform, which unifies biological sequence, structure, function, and scientific literature into a searchable, AI-ready framework. He has supported BioStrand's partnership with InterSystems to integrate advanced vector search capabilities into LENSai, enhancing AI-driven research capabilities.

ImmunoPrecise Antibodies (NASDAQ: IPA), a bio-native AI company focused on TechBio and next-generation drug discovery, has scheduled its Q4 and full fiscal year 2025 earnings conference call for July 29, 2025, at 10:30 AM ET.

The company will release its financial results before the call and host a live webcast with a Q&A session. Participants can join via phone using toll-free number (800) 715-9871 or international number +1 (646) 307-1963 with Conference ID 3224490, or through the webcast link available on IPA's investor relations website.